cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo Nordisk's 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 Novo's CagriSema loses phase 3

They add a layer to the conversation that you won't want to miss

So first of all, can you tell us a little bit about GLP-1s

GLP-1 therapy is highly effective for women over 40 because it targets appetite regulation, insulin resistance, and metabolic changes linked to aging and menopause

This was achieved by means of population PK models using frequently sampled PK profiles from nine clinical pharmacology trials

In addition, NTS neurons projecting to multiple forebrain regions contribute to both physiological and emotional regulation (50)

At the cellular level, these signaling alterations lead to decreases in insulin-induced glycolysis and increases in cell growth